Donna M. Posluszny
University of Pittsburgh
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Donna M. Posluszny.
Journal of Clinical Oncology | 2010
Athanassios Argiris; Dwight E. Heron; Ryan P. Smith; Seungwon Kim; Michael K. Gibson; Stephen Y. Lai; Barton F. Branstetter; Donna M. Posluszny; Lin Wang; Raja R. Seethala; Sanja Dacic; William E. Gooding; Jennifer R. Grandis; Jonas T. Johnson; Robert L. Ferris
PURPOSE We incorporated cetuximab, a chimeric monoclonal antibody against the epidermal growth factor receptor (EGFR), into the induction therapy and subsequent chemoradiotherapy of head and neck cancer (HNC). PATIENTS AND METHODS Patients with locally advanced HNC, including squamous and undifferentiated histologies, were treated with docetaxel 75 mg/m2 day 1, cisplatin 75 mg/m2 day 1, and cetuximab 250 mg/m2 days 1, 8, and 15 (after an initial loading dose of 400 mg/m2), termed TPE, repeated every 21 days for three cycles, followed by radiotherapy with concurrent cisplatin 30 mg/m2 and cetuximab weekly (XPE), and maintenance cetuximab for 6 months. Quality of life (QOL) was assessed using Functional Assessment of Cancer Therapy-Head and Neck. In situ hybridization (ISH) for human papillomavirus (HPV), immunohistochemistry for p16, and fluorescence ISH for EGFR gene copy number were performed on tissue microarrays. RESULTS Of 39 enrolled patients, 36 had stage IV disease and 23 an oropharyngeal primary. Acute toxicities during TPE included neutropenic fever (10%) and during XPE, grade 3 or 4 oral mucositis (54%) and hypomagnesemia (39%). With a median follow-up of 36 months, 3-year progression-free survival and overall survival were 70% and 74%, respectively. Eight patients progressed in locoregional sites, three in distant, and one in both. HPV positivity was not associated with treatment efficacy. No progression-free patient remained G-tube dependent. The H&N subscale QOL scores showed a significant decrement at 3 months after XPE, which normalized at 1 year. CONCLUSION This cetuximab-containing regimen resulted in excellent long-term survival and safety, and warrants further evaluation in both HPV-positive and -negative HNC.
Psychosomatic Medicine | 2001
Angela Liegey Dougall; Robert J. Ursano; Donna M. Posluszny; Carol S. Fullerton; Andrew Baum
Objective This study identified factors that predict individual vulnerability to psychological trauma by examining the relationships among situation and person variables and symptoms of posttraumatic stress disorder (PTSD) 1, 6, and 12 months after a serious motor vehicle accident (MVA). Methods Background characteristics, exposure variables (ie, injury severity and accident characteristics), and psychosocial variables (ie, perceived loss of control, social support, and coping) were used to predict symptoms of PTSD and recovery in 115 injured MVA victims. All participants were injured during the MVA and provided data prospectively over the course of a year after their accidents. Results Along with background and exposure variables, use of wishful thinking coping distinguished between victims with and without symptoms of PTSD. Conclusions Psychosocial variables such as wishful thinking coping can be used to identify MVA victims who are at risk of developing chronic posttraumatic stress and warrant further investigation.
General Hospital Psychiatry | 2012
Mary Amanda Dew; Andrea F. DiMartini; Annette J. DeVito Dabbs; Kristen R. Fox; Larissa Myaskovsky; Donna M. Posluszny; Galen E. Switzer; R. Zomak; Robert L. Kormos; Yoshiya Toyoda
OBJECTIVE Anxiety disorders are prominent in chronic lung disease; lung transplant recipients may therefore also be at high risk for these disorders. We sought to provide the first prospective data on rates and risk factors for anxiety disorders as well as depressive disorders during the first 2 years after transplantation. METHOD A total of 178 lung recipients and a comparison group (126 heart recipients) received psychosocial and Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition assessments at 2, 7, 12, 18 and 24 months posttransplant. Survival analysis determined onset rates and risk factors. RESULTS The panic disorder rate was higher (P<.05) in lung than heart recipients (18% vs. 8%). Lung and heart recipients did not differ on rates of transplant-related posttraumatic stress disorder (15% vs. 14%), generalized anxiety disorder (4% vs. 3%) or major depression (30% vs. 26%). Risk factors for disorders included pretransplant psychiatric history, female gender, longer wait for transplant, and early posttransplant health problems and psychosocial characteristics (e.g., poorer caregiver support and use of avoidant coping). CONCLUSIONS Heightened vigilance for panic disorder in lung recipients and major depression in all cardiothoracic recipients is warranted. Strategies to prevent psychiatric disorder should target recipients based not only on pretransplant characteristics but on early posttransplant characteristics as well.
Transplantation | 2015
Mary Amanda Dew; Emily Rosenberger; Larissa Myaskovsky; Andrea F. DiMartini; Annette J. DeVito Dabbs; Donna M. Posluszny; Jennifer L. Steel; Galen E. Switzer; Diana A. Shellmer; Joel B. Greenhouse
Background Depression and anxiety are common mental health problems in transplant populations. There is mixed evidence concerning whether they increase morbidity and mortality risks after transplantation. If such associations exist, additional risk reduction strategies may be needed. Methods Four bibliographic databases were searched from 1981 through September 2014 for studies prospectively examining whether depression or anxiety (determined with diagnostic evaluations or standardized symptom scales) affected risk for posttransplant mortality, graft loss, acute graft rejection, chronic rejection, cancer, infection, and rehospitalization. Results Twenty-seven studies (10 heart, total n = 1738; 6 liver, n = 1063; 5 kidney, n = 49515; 4 lung, n = 584; 1 pancreas, n = 80; 1 mixed recipient sample, n = 205) were identified. In each, depression and/or anxiety were typically measured before or early after transplantation. Follow-up for outcomes was a median of 5.8 years (range, 0.50-18.0). Depression increased the relative risk (RR) of mortality by 65% (RR, 1.65; 95% confidence interval [95% CI], 1.34-2.05; 20 studies). Meta-regression indicated that risk was stronger in studies that did (vs did not) control for potential confounders (P = .032). Risk was unaffected by type of transplant or other study characteristics. Depression increased death-censored graft loss risk (RR, 1.65; 95% CI, 1.21-2.26, 3 studies). Depression was not associated with other morbidities (each morbidity was assessed in 1-4 studies). Anxiety did not significantly increase mortality risk (RR, 1.39; 95% CI, 0.85-2.27, 6 studies) or morbidity risks (assessed in single studies). Conclusions Depression increases risk for posttransplant mortality. Few studies considered morbidities; the depression-graft loss association suggests that linkages with morbidities deserve greater attention. Depression screening and treatment may be warranted, although whether these activities would reduce posttransplant mortality requires study.
Psycho-oncology | 2011
Donna M. Posluszny; Robert P. Edwards; Mary Amanda Dew; Andrew Baum
Objective: We sought to examine levels of perceived threat and traumatic stress symptoms both before and in the short‐ and long‐term period after surgery and associated care in women diagnosed with gynecologic cancer or benign conditions.
American Journal of Transplantation | 2012
Larissa Myaskovsky; Donna M. Posluszny; Richard M. Schulz; Andrea F. DiMartini; Galen E. Switzer; A. DeVito Dabbs; Mary McNulty; Robert L. Kormos; Yoshiya Toyoda; Mary Amanda Dew
Cardiothoracic transplant programs generally require that transplant recipients have family caregivers to assist them posttransplant. The burden of caregiving on the family members remains poorly understood. If caregivers’ well‐being is compromised by caregiving, it may bode poorly for transplant recipients’ own health in the long‐term posttransplant. We examined caregiver health‐related quality of life (HRQOL) during the first year after their family members transplant, its predictors and its relationship to subsequent patient survival. Adult (aged 18+) caregivers of 242 cardiothoracic transplant recipients (lung = 134; heart = 108) completed assessments of demographics, psychosocial characteristics and caregiver burden at 2 months posttransplant, and HRQOL at 2, 7 and 12 months posttransplant. Recipients’ survival time was obtained from medical records. Caregiver HRQOL was generally high across the first‐year posttransplant in emotional and social functioning; caregiver physical functioning significantly worsened. There were no differences by type of recipient transplant. Greater caregiver burden predicted poorer caregiver HRQOL in several physical domains at 12 months posttransplant. Transplant recipients whose caregivers had lower perceived general health at 12 months posttransplant showed poorer survival rates during the subsequent 7 years of follow up. Transplant teams should identify those caregivers at risk for poorer general health posttransplant to maximize positive outcomes for the entire family.
Psychosomatic Medicine | 2009
Angela Liegey Dougall; Ashley Wilder Smith; Tamara J. Somers; Donna M. Posluszny; Wendy S. Rubinstein; Andrew Baum
Objective: To examine how women cope with genetic testing for heightened susceptibility to breast cancer. Methods: Participants were 126 White women (age = 44 ± 9 years) who were participants in a larger study of genetic testing for risk of different chronic diseases. All women were at higher-than-average risk for breast cancer due to a personal and/or family history and were considering genetic testing. Distress (Symptom Checklist-90-Revised, Impact of Event Scale, Perceived Stress Scale, Spielberger State-Trait Anxiety Inventory, and the Center for Epidemiological Studies Depression Scale) was assessed at four assessments; one before and three after the decision to have genetic testing. The majority of women (n = 100) had testing. The follow-up assessments occurred at 1 week after receiving results (or 3–4 months after baseline if testing was not elected), and then at 3 and 6 months after the second assessment. Coping (Brief COPE) was measured at the first and third assessments. Results: Coping was relatively stable over time and did not vary as a function of genetic test results. Active coping strategies were used more often by women with a personal cancer history than by women without cancer. Use of avoidant coping was reliably and positively associated with distress over time independent of cancer history and test result. Conclusions: The identification of specific coping styles that were associated with more or less distress is useful as a means of identifying and targeting coping interventions and predicting which participants may be at risk for distress. BRCA 1 = breast cancer 1 gene; BRCA 2 = breast cancer 2 gene; CGP = Cancer Genetics Program; SCL-90R = Symptom Checklist-90 Revised; GSI = Global Severity Index; MANCOVA = multivariate analysis of covariance.
Head and Neck-journal for The Sciences and Specialties of The Head and Neck | 2015
Donna M. Posluszny; Angela Liegey Dougall; Jonas T. Johnson; Athanassios Argiris; Robert L. Ferris; Andrew Baum; Dana H. Bovbjerg; Mary Amanda Dew
Head and neck cancer is a life‐threatening illness requiring aversive treatments. Despite clear potential for posttraumatic stress disorder (PTSD) symptoms in both patients and their partners, research is scant.
Journal of Psychosocial Oncology | 2014
Carissa A. Low; Ellen Burke Beckjord; Dana H. Bovbjerg; Mary Amanda Dew; Donna M. Posluszny; John E. Schmidt; Amy Lowery; Stephanie Nutt; Sarah R. Arvey; Ruth Rechis
Positive health-promoting behaviors, including lifestyle factors (e.g., physical activity) and appropriate health service utilization (e.g., screening for secondary cancers), can minimize the health risks and challenges facing cancer survivors. The goal of this article is to examine factors associated with positive health behaviors in 2,615 posttreatment cancer survivors who completed the 2010 LIVESTRONG survey. Multivariate logistic regression was used to model odds of reporting each of six positive health behaviors “as a result of your experience with cancer”: three “healthy lifestyle” behaviors and three “health care utilization” behaviors. In fully adjusted models, factors associated with greater likelihood of engaging in positive lifestyle behaviors (e.g., physical activity, changing diet) included sociodemographic factors, greater knowledge about how to reduce cancer risk; and reporting more psychological benefits due to cancer (ps <.01). Factors associated with greater likelihood of attending medical appointments and obtaining recommended cancer screenings included older age, better patient–provider communication, greater knowledge about how to reduce cancer risk, and more psychological benefits of cancer (ps <.01). Results suggest that knowledge about how to prevent cancer and benefit finding after cancer are related to positive health behaviors broadly, whereas better patient–provider communication is associated with positive cancer screening and health care utilization but not healthy lifestyle behaviors. Clinical interventions targeting these modifiable factors could maximize positive health behavior changes among cancer survivors, affecting risk for cancer recurrence as well as overall health and well-being.
Journal of Psychosocial Oncology | 2011
Donna M. Posluszny; Andrew Baum; Robert P. Edwards; Mary Amanda Dew
The authors sought to examine levels and predictors of posttraumatic growth over one year after surgery in women diagnosed with gynecologic cancer or benign conditions necessitating surgical intervention. Women with advanced-stage cancer (n = 16), early-stage cancer (n = 18), benign gynecologic disease (n = 21), and no disease (n = 14; postannual pelvic exam) completed questionnaires (Perceived Threat, PTSD Checklist [PCL]) 1 week prior to surgery and completed the Posttraumatic Growth Inventory (PTGI) 16 months postsurgery. The four groups’ scores varied significantly on the PTGI. The three disease groups reported higher levels of posttraumatic growth than the no disease group. Higher PCL score presurgery and greater disease severity were positively related to posttraumatic growth, and higher income level was negatively related to posttraumatic growth. Women with gynecologic cancer, regardless of stage, and women with benign gynecologic conditions experience posttraumatic growth.
Collaboration
Dive into the Donna M. Posluszny's collaboration.
University of Texas Health Science Center at San Antonio
View shared research outputs